Roche has announced that the Phase 3 IMpower130 study met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS). The combination of atezolizumab (Tecentriq, Roche) plus chemotherapy (carboplatin and albumin-bound paclitaxel; nab-paclitaxel [Abraxane, Celgene Corp.]) helped people live significantly longer compared to chemotherapy alone in the initial, first-line treatment of advanced nonsquamous non–small-cell lung cancer (NSCLC). In addition, the atezolizumab combination reduced the risk of disease worsening or death (PFS) compared with chemotherapy alone. Safety for the atezolizumab and chemotherapy combination appeared consistent with the known safety profile of the individual medicines, and no new safety signals were identified with the combination.
Currently, Roche has eight phase 3 lung cancer studies underway evaluating atezolizumab alone or in combination with other medicines. This is the third positive phase 3 study evaluating atezolizumab alone or in combination to demonstrate an OS benefit for people with NSCLC.
Atezolizumab is a monoclonal antibody designed to bind with a protein called programmed death ligand-1 (PD-L1) expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, atezolizumab may enable the activation of T cells. Atezolizumab has the potential to be used as a foundational combination partner with cancer immunotherapies, targeted medicines and various chemotherapies across a broad range of cancers.
Atezolizumab is already approved in the European Union, United States, and more than 70 countries for people with previously treated metastatic NSCLC and for people with locally advanced or metastatic urothelial cancer (mUC) who are not eligible for cisplatin chemotherapy, or who have had disease progression during or following platinum-containing therapy.
Source: Roche; May 29, 2018.